Diflucortolone 21-valerate
(Synonyms: 戊酸双氟可龙) 目录号 : GC48491A glucocorticoid
Cas No.:59198-70-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Diflucortolone 21-valerate is a glucocorticoid.1 It has anti-inflammatory effects in a rat model of croton oil-induced ear edema when applied topically (ED50 = 9.7 µg/ml).2 Diflucortolone 21-valerate (0.1%) also induces skin inflammation and thins the epidermis in hairless dogs following chronic topical administration and increases allergic- and non-allergic-mediated skin inflammation in mouse models of atopic dermatitis when applied topically prior to and following sensitization.3,1 Formulations containing diflucortolone 21-valerate have been used in the treatment of inflammatory or allergic skin conditions.
1.Igawa, K., Katayama, I., Minatohara, K., et al.Topical glucocorticoid augments both allergic and non-allergic cutaneous reactions in mice when applied at the afferent stage of contact sensitivityAllergol. Int.46(1)33-41(1997) 2.Yamada, K., Hattori, S., Hakoda, T., et al.A fundamental study on a bioassay for the antiphlogistic effect of topically applied antiinflammatory agentsNihon Yakurigaku Zasshi75(8)789-798(1979) 3.Kimura, T., and Doi, K.Dorsal skin reactions of hairless dogs to topical treatment with corticosteroidsToxicol. Pathol.27(5)528-535(1999)
| Cas No. | 59198-70-8 | SDF | |
| 别名 | 戊酸双氟可龙 | ||
| Canonical SMILES | F[C@@]12[C@](C[C@@H](C([C@@]2(C=C3)C)=CC3=O)F)([H])[C@@]4([H])[C@](C[C@@H]1O)([C@H]([C@@H](C4)C)C(COC(CCCC)=O)=O)C | ||
| 分子式 | C27H36F2O5 | 分子量 | 478.6 |
| 溶解度 | DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:3): 0.25 mg/ml,DMSO: 10 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0894 mL | 10.4471 mL | 20.8943 mL |
| 5 mM | 0.4179 mL | 2.0894 mL | 4.1789 mL |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0894 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Anti-inflammatory effects of methylprednisolone aceponate in animals]
Nihon Yakurigaku Zasshi 1991 Nov;98(5):409-17.PMID:1813371DOI:10.1254/fpj.98.5_409.
In the case of dermal application of the drugs to croton oil-induced ear edema in rats and picryl chloride-induced delayed type hypersensitivity in mice, the anti-inflammatory effect of methylprednisolone aceponate (MPA) was slightly weaker than those of clobetasol 17-propionate and Diflucortolone 21-valerate, but stronger than those of hydrocortisone 17-butyrate and hydrocortisone 17-butyrate 21-propionate. Betamethasone 17-valerate applied dermally was less and more effective than MPA to ear edema in rats and delayed type hypersensitivity in mice, respectively. The anti-inflammatory effect of MPA was weaker in subcutaneous administration than in topical application to the two inflammatory models. It was suggested that MPA has strong anti-inflammatory effects and weak systemic effects by topical application. Methylprednisolone 17-propionate (MP-17P) and methylprednisolone (MP), unesterified in only the C-21 position and in both the C-17 and 21 positions of MPA, respectively, showed weaker anti-inflammatory activities than MPA by topical application to croton oil-induced ear edema. The ratio of the anti-inflammatory effects by topical application to subcutaneous administration of MPA was higher than those of MP-17P and MP. The excellent characteristics of MPA as a dermal anti-inflammatory drug are suggested to be derived from di-esterification of MP, which has a weak activity intrinsically.